PwPepwise

Ziconotide

Pain & Nerves

a.k.a. Prialt

ω-conotoxin MVIIA (N-type Ca channel blocker)

Ziconotide is a synthetic pain-relieving peptide derived from the venom of the marine cone snail Conus magus.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Slow-titration protocol (recommended for chronic pain)0.1 mcg———
Earlier rapid-titration protocols (not recommended)0.4 mcg———
Acute postoperative setting (investigational)0.7 mcg———

Approximate values pulled from the research — double-check before dosing.

§01Summary

Ziconotide is a synthetic pain-relieving peptide derived from the venom of the marine cone snail Conus magus. It works by blocking a specific type of calcium channel (N-type) in the spinal cord, interrupting pain signal transmission at its source — a mechanism entirely distinct from opioids. Because it is delivered directly into the fluid surrounding the spinal cord (intrathecally), ziconotide bypasses the brain's opioid receptors entirely, making it the only FDA-approved non-opioid intrathecal analgesic available today11.

In patients with severe chronic pain who have not responded to conventional therapies, intrathecal ziconotide reduces pain intensity scores significantly compared to placebo1,2,3. Clinical trials enrolling cancer, AIDS, and chronic noncancer pain patients show that roughly half of cancer/AIDS-related pain patients and one-sixth to one-third of noncancer chronic pain patients achieve meaningful pain relief11. Importantly, ziconotide does not appear to produce tolerance over time, distinguishing it from opioid-based intrathecal therapies20,13. Its use is associated with central nervous system side effects — including dizziness, confusion, and memory impairment — that are most pronounced with rapid dose escalation and that resolve upon dose reduction or discontinuation3,6.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Ziconotide (also known as SNX-111 and marketed as Prialt) is a 25-amino acid polybasic peptide that functions as a highly selective blocker of N-type voltage-sensitive calcium channels (N-VSCCs), specifically the Cav2.2 α1 subunit10,20. N-type calcium channels are concentrated at the presynaptic terminals of primary afferent nociceptive neurons (C-fibers and Aδ-fibers) in the superficial layers of the spinal cord dorsal horn (laminae I and II, substantia gelatinosa)9,17. By occluding the Cav2.2 channel pore, ziconotide prevents calcium influx into presynaptic terminals in response to depolarization, thereby inhibiting the release of pronociceptive neurotransmitters including substance P, calcitonin gene-related peptide (CGRP), and glutamate — attenuating spinal nociceptive transmission at the first synapse9,20.

High-resolution cryo-EM structural studies have elucidated the molecular basis of ziconotide's selectivity for Cav2.2. The peptide is coordinated by the P1 and P2 helices supporting the selectivity filter and extracellular loops in repeats II, III, and IV of the α1 subunit10. Binding induces a conformational change in which the extracellular loop of repeat III and the α2δ-1 subunit tilt upward concertedly to accommodate the peptide10. An additional structurally noteworthy feature is a phosphatidylinositol 4,5-bisphosphate (PIP2) molecule that stabilizes the down conformation of the repeat II voltage-sensing domain (VSD-II), providing an unexpected mechanism of lipid-mediated channel regulation that may inform next-generation analog design10.

Because ziconotide acts on voltage-gated rather than ligand-gated channels and does not interact with opioid receptors, it lacks cross-tolerance with opioids and does not produce the receptor desensitization or downregulation characteristic of chronic opioid use20,13. This mechanistic distinction accounts for the absence of tolerance development observed over extended intrathecal therapy13,20.

Ziconotide is a large, highly polar peptide and does not cross the blood-brain barrier meaningfully when administered intrathecally; systemic absorption is minimal via this route, which accounts for the requirement for direct intrathecal delivery to achieve therapeutic spinal concentrations9,11. Because L-type calcium channel blockade does not produce intrathecal analgesia, the N-type selectivity of ziconotide is pharmacologically essential for its analgesic mechanism, as confirmed in early clinical dose-finding work6. The selectivity for Cav2.2 over Cav1.x (L-type) and Cav2.1 (P/Q-type) channels underpins both its analgesic efficacy and its characteristic CNS adverse event profile when supratherapeutic concentrations reach higher neural structures.

§04Evidence & efficacy

Evidence base
270Studies
129Human
34Animal

Intrathecal ziconotide reduces pain intensity in patients with severe chronic pain refractory to conventional systemic and intrathecal therapies. In a landmark RCT of cancer and AIDS patients with refractory pain, ziconotide produced a mean VASPI score improvement of 53.1% compared to 18.1% for placebo (p<0.001), with 52.9% of ziconotide patients achieving moderate to complete pain relief versus 17.5% of placebo patients1. In a separate slow-titration RCT enrolling severe chronic pain patients, ziconotide produced a 14.7% mean VASPI improvement versus 7.2% for placebo (p=0.036)2. In a chronic nonmalignant pain RCT, ziconotide produced a 31.2% mean VASPI reduction compared to 6.0% for placebo (p≤0.001)3.

A meta-analysis of three RCTs reported a pooled odds ratio of 2.77 (95% CI: 1.37–5.59) for pain responders on ziconotide versus placebo5. Response rates across indications range from approximately one-sixth to one-third of noncancer chronic pain patients and approximately one-half of cancer/AIDS-related pain patients11. Analgesic effects appear durable in responders, and a 12-month prospective study reported a mean 36.9% VASPI reduction from baseline (p<0.0001) without evidence of tolerance development13.

The absence of analgesic tolerance over extended treatment distinguishes ziconotide from opioid-based intrathecal therapies and has been observed consistently across both preclinical and clinical datasets20,13. Efficacy has been demonstrated across malignant and nonmalignant pain populations13, with higher response rates observed in cancer and AIDS-related pain compared to noncancer chronic pain11.

§05Safety

Ziconotide carries a well-characterized adverse event profile that is predominantly neurological and CNS-related, reflecting its mechanism of action at spinal and supraspinal calcium channels. The most commonly reported adverse events include dizziness, confusion, nausea, headache, somnolence, ataxia, memory impairment, abnormal gait, nystagmus, and urinary retention2,3,6,12. In a large long-term open-label study, 99.7% of patients experienced at least one adverse event, though 43.5% were mild and 42.3% moderate in severity, and 58.6% were deemed unrelated to ziconotide12. Discontinuation due to adverse events occurred in approximately 39.4% of patients in a 12-month prospective study13.

Adverse events are strongly dose- and titration-rate-dependent. Rapid titration protocols produced substantially higher rates of serious CNS adverse events and required mid-study protocol amendments in two of three pivotal RCTs3,5. Slow titration to lower mean doses significantly improved the tolerability profile, with discontinuation rates due to adverse events comparable to placebo in one slow-titration RCT2.

Clinically significant creatine kinase elevations (greater than 3× the upper limit of normal) occurred in approximately 5.7% of patients at one month of therapy, with partial normalization over time, warranting ongoing monitoring for potential myopathy12. No drug-related deaths, intrathecal catheter-tip granulomas, or permanent adverse sequelae were observed in long-term data — a notable safety distinction from intrathecal opioid therapy12. All CNS adverse events observed in early dose-finding studies resolved upon drug discontinuation, indicating reversibility6.

Neuropsychiatric effects including hallucinations and cognitive disturbances are recognized adverse effects requiring clinical vigilance18. The drug has a narrow therapeutic window, and its use is appropriately limited to experienced centers with access to implantable drug delivery systems9,11.

§06History

Ziconotide originates from omega-conotoxin MVIIA, a peptide isolated from the venom of the predatory marine cone snail Conus magus found in the Indo-Pacific region20. Cone snail venoms contain hundreds of neuroactive peptides (conotoxins) evolved to paralyze prey, and omega-conotoxins were identified in the 1980s as potent blockers of neuronal calcium channels. Researchers recognized the analgesic potential of N-type calcium channel blockade given the channel's established role in spinal nociceptive neurotransmission, and synthetic production of the 25-amino acid peptide — renamed ziconotide — enabled systematic preclinical and clinical development20,9.

Preclinical studies demonstrated superior anti-nociceptive activity compared to morphine in pain models where opioids perform poorly, and crucially, no tolerance development with repeated administration20. Clinical development proceeded through the 1990s and early 2000s, with pivotal Phase III randomized controlled trials published between 2000 and 20061,2,3,6. An early postoperative pain RCT published in 2000 established proof-of-concept for intrathecal N-type blockade6, followed by pivotal chronic pain trials1,3,2.

Ziconotide received FDA approval in December 2004 under the trade name Prialt for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other therapies9,11. European Medicines Agency (EMA) approval followed. A landmark Lancet review in 2010 cemented its status as the first selective N-type calcium channel blocker approved for clinical use9. Structural characterization of the Cav2.2–ziconotide complex via cryo-EM, published in Nature in 2021, provided atomic-level insight into its binding mechanism and established a framework for rational design of next-generation analgesic peptides10. Active clinical investigation continues across multiple pain indications, including spinal cord injury–related neuropathic pain14.

§07References